A Phase 3, Open-Label, Follow-On Study of Multiple Courses of Aztreonam Lysinate for Inhalation (AI) in Cystic Fibrosis Patients (AIR-CF3).

Trial Profile

A Phase 3, Open-Label, Follow-On Study of Multiple Courses of Aztreonam Lysinate for Inhalation (AI) in Cystic Fibrosis Patients (AIR-CF3).

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2011

At a glance

  • Drugs Aztreonam (Primary)
  • Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms AIR-CF3
  • Sponsors Corus Pharma; Gilead Sciences
  • Most Recent Events

    • 12 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 May 2008 6-month results reported at ATS 2008
    • 15 Jun 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top